NASDAQ : JBIO
Jade Biosciences, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 14.24 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 905.63M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Selling, General & Admin | 28.07M | 20.42M | 8.61M |
| Research & Development | 136.67M | 93.12M | 55.87M |
| Operating Expenses | 164.74M | 113.54M | 64.48M |
| Operating Income | -164.74M | -113.54M | -64.48M |
| Interest Expense | -3.60M | -3.60M | |
| Interest & Investment Income | 11.67M | 7.78M | 2.32M |
| Other Non Operating Income (Expenses) | 3.52M | 3.59M | |
| EBT Excluding Unusual Items | -153.15M | -105.77M | -62.16M |
| Other Unusual Items | -21.58M | -31.80M | |
| Pretax Income | -153.15M | -127.35M | -93.96M |
| Income Tax Expense | 89.00K | 58.00K | |
| Net Income | -153.24M | -127.41M | -93.96M |
| Preferred Dividends & Other Adjustments | -28.80M | -27.27M | |
| Net Income to Common | -124.44M | -100.14M | -93.96M |
| Shares Outstanding (Basic) | 53.11M | 31.36M | 3.16M |
| Shares Outstanding (Diluted) | 53.11M | 31.36M | 3.16M |
| EPS (Basic) | -2.34 | -3.19 | -29.78 |
| EPS (Diluted) | -2.34 | -3.19 | -29.78 |
| Free Cash Flow | -123.57M | -94.89M | -45.23M |
| Free Cash Flow Per Share | -2.33 | -3.03 | -14.33 |
| EBITDA | -164.70M | -113.52M | |
| D&A For EBITDA | 39.00K | 26.00K | |
| EBIT | -164.74M | -113.54M | -64.48M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Cash & Equivalents | 107.25M | 88.44M | 69.39M |
| Short-Term Investments | 353.95M | 247.72M | |
| Cash & Short-Term Investments | 461.20M | 336.16M | 69.39M |
| Prepaid Expenses | 10.05M | 12.66M | 268.00K |
| Total Current Assets | 471.25M | 348.82M | 69.65M |
| Property, Plant & Equipment | 793.00K | 896.00K | |
| Other Long-Term Assets | 69.00K | 69.00K | 3.15M |
| Total Assets | 472.11M | 349.78M | 72.80M |
| Accounts Payable | 5.82M | 2.02M | 1.29M |
| Accrued Expenses | 15.22M | 14.39M | 9.63M |
| Current Portion of Leases | 761.00K | 127.00K | |
| Other Current Liabilities | 9.77M | 1.08M | |
| Total Current Liabilities | 31.57M | 16.54M | 12.00M |
| Long-Term Debt | 107.60M | ||
| Long-Term Leases | 628.00K | 724.00K | |
| Total Liabilities | 32.20M | 17.26M | 119.60M |
| Common Stock | 6.00K | 5.00K | 1.00K |
| Additional Paid-In Capital | 711.09M | 506.77M | 179.00K |
| Retained Earnings | -270.52M | -174.39M | -46.98M |
| Comprehensive Income & Other | -660.00K | 129.00K | |
| Total Common Equity | 439.91M | 332.52M | -46.80M |
| Shareholders' Equity | 439.92M | 332.52M | -46.80M |
| Total Liabilities & Equity | 472.11M | 349.78M | 72.80M |
| Total Debt | 1.39M | 851.00K | 107.60M |
| Net Cash (Debt) | 459.82M | 335.31M | -38.21M |
| Net Cash Per Share | 8.66 | 10.69 | -12.11 |
| Filing Date Shares Outstanding | 63.60M | 49.32M | 5.82M |
| Total Common Shares Outstanding | 63.56M | 49.32M | 5.82M |
| Working Capital | 439.68M | 332.28M | 57.66M |
| Book Value Per Share | 6.92 | 6.74 | -8.04 |
| Tangible Book Value | 439.91M | 332.52M | -46.80M |
| Tangible Book Value Per Share | 6.92 | 6.74 | -8.04 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Net Income | -153.24M | -127.41M | -93.96M |
| Depreciation & Amortization | 39.00K | 26.00K | |
| Loss (Gain) From Sale of Investments | -1.64M | -784.00K | |
| Stock-Based Compensation | 34.70M | 20.01M | 2.51M |
| Other Operating Activities | 60.00K | 21.67M | 25.20M |
| Change in Accounts Payable | -149.00K | 361.00K | 2.58M |
| Change in Other Net Operating Assets | -3.29M | -8.56M | 18.44M |
| Operating Cash Flow | -123.51M | -94.69M | -45.23M |
| Capital Expenditures | -60.00K | -196.00K | |
| Investment in Securities | -352.88M | -246.78M | |
| Other Investing Activities | -31.00K | -31.00K | |
| Investing Cash Flow | -352.97M | -247.01M | |
| Total Debt Issued | -205.00M | 190.00M | |
| Net Debt Issued (Repaid) | -205.00M | 190.00M | |
| Issuance of Common Stock | 578.95M | 385.38M | |
| Other Financing Activities | -11.06M | -24.62M | -6.00M |
| Financing Cash Flow | 362.89M | 360.77M | 184.00M |
| Foreign Exchange Rate Adjustments | -98.00K | -21.00K | |
| Net Cash Flow | -113.69M | 19.05M | 138.77M |
| Free Cash Flow | -123.57M | -94.89M | -45.23M |
| Free Cash Flow Per Share | -2.33 | -3.03 | -14.33 |
| Levered Free Cash Flow | -61.35M | ||
| Unlevered Free Cash Flow | -59.10M | ||
| Change in Working Capital | -3.44M | -8.20M | 21.02M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Market Capitalization | 894.18M | 709.84M | |
| Enterprise Value | 434.36M | 511.81M | |
| Last Close Price | 14.06 | 15.43 | |
| PB Ratio | 2.03 | 2.13 | |
| P/TBV Ratio | 2.03 | 2.13 | |
| Debt / Equity Ratio | 0.00 | 0.00 | -2.30 |
| Net Debt / Equity Ratio | -1.04 | -1.01 | -0.82 |
| Net Debt / EBITDA Ratio | 2.79 | 2.95 | |
| Net Debt / FCF Ratio | 3.72 | 3.53 | -0.84 |
| Quick Ratio | 14.61 | 20.32 | 5.78 |
| Current Ratio | 14.93 | 21.09 | 5.81 |
| Return on Equity (ROE) | -89.19% | ||
| Return on Assets (ROA) | -33.59% | ||
| Return on Capital Employed (ROCE) | -37.40% | -34.10% | -106.00% |
| Earnings Yield | -16.67% | -17.95% | |
| FCF Yield | -13.82% | -13.37% | |
| Buyback Yield / Dilution | -893.82% |